Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Blau FarmaceuticaBSP:BLAU3 -0.77%87 OCF Yield % is 13.15 as of Jul. 24, 2026, which is 48% above its 10-year median of 8.90. GuruFocus rates BSP:BLAU3 with a GF Score™ of 87/100 and a GF Value™ of R$11.17 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Blau Farmaceutica ranks better than 86.08% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Blau Farmaceutica OCF Yield % Related Terms
Blau Farmaceutica OCF Yield % Historical Data
* Premium members only.
The historical data trend for Blau Farmaceutica's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:BLAU3 vs ZTS, UTHR, VTRS: OCF Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Blau Farmaceutica's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Blau Farmaceutica OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Blau Farmaceutica's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Blau Farmaceutica's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Blau Farmaceutica (BSP:BLAU3) has a OCF Yield % of 13.15 as of Jul. 24, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Blau Farmaceutica and its competitors. This is 48% above median its historical median of 8.90. Over the past decade, Blau Farmaceutica's OCF Yield % has ranged from 1.52 to 26.29. According to the industry distribution chart, Blau Farmaceutica ranks #140 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 13.9%.
Is Blau Farmaceutica's OCF Yield % too high?
Blau Farmaceutica's current OCF Yield % of 13.15 is 48% above median its 10-year median of 8.90. Over the past 10 years, this metric has ranged from a low of 1.52 to a high of 26.29. The Drug Manufacturers industry median OCF Yield % is 3.66. Blau Farmaceutica's value of 13.15 is 259.3% above this industry median. Based on the distribution chart, Blau Farmaceutica ranks #140 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Blau Farmaceutica has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Blau Farmaceutica's OCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Blau Farmaceutica ranks #140 out of 1006 companies for OCF Yield %. This places Blau Farmaceutica in the top 14% of its industry — outperforming the majority of peers. The industry median OCF Yield % is 3.66. Blau Farmaceutica's value of 13.15 is 259.3% above this benchmark. Historically, Blau Farmaceutica's own OCF Yield % has ranged from 1.52 to 26.29 over the past decade. While the company's 10-year median is 8.90 vs. the industry median of 3.66, Blau Farmaceutica has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.66, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Blau Farmaceutica's current OCF Yield % of 13.15 is 259.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Blau Farmaceutica and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Blau Farmaceutica's current OCF Yield % is 13.15, which is 48% above median its own 10-year median of 8.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Blau Farmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Blau Farmaceutica (BSP:BLAU3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$11.17, compared to a current price of R$8.98 — trading 19.6% below its estimated fair value. The current OCF Yield % is 13.15, which is 48% above median its 10-year median of 8.90 and 259.3% above the Drug Manufacturers industry median of 3.66. Blau Farmaceutica's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Blau Farmaceutica (BSP:BLAU3), the current OCF Yield % is 13.15 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Blau Farmaceutica (BSP:BLAU3) Overvalued in 2026?
Based on GuruFocus' analysis, Blau Farmaceutica stock appears to be undervalued.
The current stock price of R$8.98 is trading 19.6% below its estimated GF Value™ of R$11.17.
GuruFocus considers Blau Farmaceutica to be Modestly Undervalued.
Key valuation signals for BSP:BLAU3:
OCF Yield %: 13.15 (48% above median its 10-year median of 8.90)
GF Value™: R$11.17 vs. price of R$8.98 (19.6% below fair value)
Industry Position: 259.3% above the Drug Manufacturers median (#140 of 1006)
No single metric tells the full story. See the BSP:BLAU3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Blau Farmaceutica SA is engaged in the manufacturing, development and commercialization of complex private-label drugs for the institutional segment. The Company's business activities cover institutional and retail segments, and are divided into four units: 1) Biologicals are a heterogeneous class of products that can be produced using raw materials from biological materials and biotechnological procedures. 2) Oncology line is made up of oral and injectable drugs intended for treating cancer, which encompasses a number of therapeutic classes. 3) Specialties line is made up of products that are used in the hospital's daily routine, in the specialized treatments for infectious diseases and special treatments. 4) Others consist of prescription and non-prescription over-the-counter drugs.
87GF Score
Get the complete analysis for BSP:BLAU3
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:BLAU3 has been successfully added to your 
